Results 141 to 150 of about 233,135 (260)

Basal-Celled Carcinoma of the Palate [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1937
openaire   +2 more sources

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Super giant basal cell carcinoma in the setting of neglect: A case report. [PDF]

open access: yesJAAD Case Rep
Lim H   +4 more
europepmc   +1 more source

Spheroid‐On‐A‐Drop: A Modular Droplet Microfluidics Platform

open access: yesAdvanced Materials Technologies, EarlyView.
The proposed Spheroid‐on‐a‐Drop platform represents a reproducible and tunable platform for the fabrication of biocompatible GelMA‐based microgels, able to support controlled 3D tumor spheroid culture. Its precise control over droplet dynamics and cell distribution paves the way for advanced applications in tissue modeling, drug screening, and ...
A. Fergola   +8 more
wiley   +1 more source

Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic

open access: yesAdvanced Robotics Research, EarlyView.
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang   +5 more
wiley   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

open access: yesAdvanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin   +20 more
wiley   +1 more source

Primary periocular basal cell carcinoma: recurrence, risk factors and follow-up. [PDF]

open access: yesAn Bras Dermatol
Bezerra RG   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy